EX-99.1
5
ex99-1.htm
Exhibit
99.1
USA
Equities Corp. Acquires Allergi
End
®
Assets
●
Acquisition
Strengthens USAQ Business Model and Strategic Position
●
Purchase
includes Al
lergi
End
®
Method Patent, Trademark and Website
●
Al
lergi
End
®
's
Product Portfolio Favorably Aligned with Industry Growth Drivers and Trends
West
Palm Beach, FL - June 24, 2021 - USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions
and physician-directed digital medicine, today announced it has acquired the method patent, trademark and website associated with
Al
lergi
End
®
's diagnostic and allergen immunotherapy product
portfolio from
MedScience Research Group, Inc.
"We
continue to strengthen our growing medical device technology and software platform with today's announced acquisition of the Al
lergi
End
®
intellectual properties. These properties are a great strategic fit that further support our recurring revenue business
model focused on non-specialist medical practitioners, which is a large and growing addressable market. We are very well positioned in
this market given our deep applications expertise and industry relationships,"
said Troy Grogan, CEO of USA Equities Corp.
"Al
lergi
End
®'
's
FDA-cleared diagnostic equipment and products allow primary care providers to diagnose and treat many common chronic allergies
in their offices. In particular, the number of people in the U.S. affected by allergic disorders, currently estimated to be 60 million,
is expected to grow at a double-digit rate while the number of full-time-equivalent allergists and immunologists is expected to decline.
In addition to addressing these secular trends and enhancing patient quality of life, Al
lergi
End
®
treatment solutions are also reimbursable from Medicare and commercial insurance providers, further driving revenue
opportunities for physicians in their own practices.
"The
acquisition of the Al
lergi
End
®
assets
also
provides USAQ the opportunity to more fully integrate and leverage the product portfolio across our marketing platform, customer relationships
and cost structure, which we expect will facilitate improvement in our margin profile over time. Finally, our pipeline of organic growth
opportunities remains active and focused on expanding our distribution channels and product portfolio", concluded Grogan
About
USA Equities Corp.
USA
Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized
medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company's
products are intended to allow general practice physicians and other medical practitioners to increase revenues by cost effectively diagnosing
and treating chronic diseases that are generally referred to specialists. The Company's products and information service portfolio
are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our
principal objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely
and specific clinical decision-making information for practicing physicians and other health care providers to address today's
allergy prone, obese, diabetic and cardiovascular diseased populations.
For
additional information, visit the Company's website at www.USAQCorp.com
Forward-Looking
Statements
Certain
matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in
the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking
statements. Forward-looking statements are generally identified by words such as "may", "could", "believes",
"estimates", "targets", "expects", or "intends" and other similar words that express
risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing
of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates,
projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including
general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in
the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially
different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this
press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events
or circumstances.
Investor
& Media Contact:
Olivia
Giamanco
USA
Equities Corp
(929)
379-6503
IR@USAQCORP.COM

EX - 99 . 1 5 ex99 - 1 . htm Exhibit 99 . 1 USA Equities Corp . Acquires Allergi End ® Assets ● Acquisition Strengthens USAQ Business Model and Strategic Position ● Purchase includes Al lergi End ® Method Patent , Trademark and Website ● Al lergi End ® 's Product Portfolio Favorably Aligned with Industry Growth Drivers and Trends West Palm Beach , FL - June 24 , 2021 - USA Equities Corp . ( OTCQB : USAQ ) , a company focused on value - based healthcare solutions and physician - directed digital medicine , today announced it has acquired the method patent , trademark and website associated with Al lergi End ® 's diagnostic and allergen immunotherapy product portfolio from MedScience Research Group , Inc . " We continue to strengthen our growing medical device technology and software platform with today 's announced acquisition of the Al lergi End ® intellectual properties . These properties are a great strategic fit that further support our recurring revenue business model focused on non - specialist medical practitioners , which is a large and growing addressable market . We are very well positioned in this market given our deep applications expertise and industry relationships , " said Troy Grogan , CEO of USA Equities Corp . " Al lergi End ® ' 's FDA - cleared diagnostic equipment and products allow primary care providers to diagnose and treat many common chronic allergies in their offices . In particular , the number of people in the U . S . affected by allergic disorders , currently estimated to be 60 million , is expected to grow at a double - digit rate while the number of full - time - equivalent allergists and immunologists is expected to decline . In addition to addressing these secular trends and enhancing patient quality of life , Al lergi End ® treatment solutions are also reimbursable from Medicare and commercial insurance providers , further driving revenue opportunities for physicians in their own practices . " The acquisition of the Al lergi End ® assets also provides USAQ the opportunity to more fully integrate and leverage the product portfolio across our marketing platform , customer relationships and cost structure , which we expect will facilitate improvement in our margin profile over time . Finally , our pipeline of organic growth opportunities remains active and focused on expanding our distribution channels and product portfolio " , concluded Grogan About USA Equities Corp . USA Equities Corp . ( OTCQB : USAQ ) is focused on providing value - based healthcare solutions , clinical informatics and algorithmic personalized medicine including digital therapeutics , behavior - based remote patient monitoring , chronic care and preventive medicine . The Company 's products are intended to allow general practice physicians and other medical practitioners to increase revenues by cost effectively diagnosing and treating chronic diseases that are generally referred to specialists . The Company 's products and information service portfolio are directed toward prevention , early detection , management and reversal of allergies , cardio - metabolic and other chronic diseases . Our principal objectives are to develop proprietary software tools , point of care devices and approaches , providing more granular , timely and specific clinical decision - making information for practicing physicians and other health care providers to address today 's allergy prone , obese , diabetic and cardiovascular diseased populations . For additional information , visit the Company 's website at www.USAQCorp.com Forward - Looking Statements Certain matters discussed in this press release are " forward - looking statements " intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995 . In particular , the Company 's statements regarding trends in the marketplace , future revenues , future products and potential future results and acquisitions , are examples of such forward - looking statements . Forward - looking statements are generally identified by words such as " may " , " could " , " believes " , " estimates " , " targets " , " expects " , or " intends " and other similar words that express risks and uncertainties . These statements are subject to numerous risks and uncertainties , including , but not limited to , the timing of the introduction of new products and the acceptance of these products , the inherent discrepancy in actual results from estimates , projections and forecasts made by management , regulatory delays , changes in government funding and budgets , and other factors , including general economic conditions , not within the Company 's control . The factors discussed herein and expressed from time to time in the Company 's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements . The forward - looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward - looking statements to reflect subsequent events or circumstances . Investor & Media Contact : Olivia Giamanco USA Equities Corp ( 929 ) 379 - 6503 IR@USAQCORP.COM